Adalimumab safety in global clinical trials of patients with Crohnʼs disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Adalimumab safety in global clinical trials of patients with Crohnʼs disease

Published:2009-09 Issue:9 Volume:15 Page:1308-1319
ISSN:1078-0998
Container-title:Inflammatory Bowel Diseases
language:en
Short-container-title:Inflammatory Bowel Diseases

Author:

Colombel Jean-Frédéric,Sandborn William J.,Panaccione Remo,Robinson Anne M.,Lau Winnie,Li Ju,Cardoso Alexandra T.

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,Immunology and Allergy

Reference23 articles.

1. A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease

2. Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease

3. Efficacy and safety of retreatment with anti–tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease

4. Infliximab Maintenance Therapy for Fistulizing Crohn's Disease

5. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Cited by 114 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid‐free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's disease;Alimentary Pharmacology & Therapeutics;2024-07-25

2. Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients;Inflammopharmacology;2024-07-10

3. Efficacy and safety of adalimumab in pediatric patients with Crohn’s disease: A systematic review and meta-analysis;European Journal of Clinical Pharmacology;2023-12-29

4. De-escalation of Biologic Treatment in Inflammatory Bowel Disease: A Comprehensive Review;Journal of Crohn's and Colitis;2023-11-01

5. Bidirectional association between infectious gastroenteritis and inflammatory bowel disease: a population-based study;European Journal of Medical Research;2023-09-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3